Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsLaurus labs

    Laurus Labs

    Jump to

    • Chartist Talk: Sudeep Shah says Nifty IT may beat its June swing high next month; flags two stocks

      The Nifty IT index is trading comfortably above its 200-day EMA, reinforcing the ongoing strength in its structure, said Sudeep Shah.

    • Reduce Laurus Labs; target of Rs 900: Deven Choksey

      Deven Choksey recommended reduce rating on Laurus Labs with a target price of Rs 900 in its research report dated October 28, 2025.

    • Laurus Labs Consolidated September 2025 Net Sales at Rs 1,653.47 crore, up 35.12% Y-o-Y

    • Laurus Labs Standalone September 2025 Net Sales at Rs 1,566.60 crore, up 32.22% Y-o-Y

    • Buy Laurus Labs; target of Rs 1110: Motilal Oswal

      Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 1110 in its research report dated October 23, 2025.

    • Buy Laurus Labs; target of Rs 1085: Choice Equity Broking

      Choice Equity Broking is bullish on Laurus Labs has recommended buy rating on the stock with a target price of Rs 1085 in its research report dated October 24, 2025.

    • Laurus Labs: Is the healthy growth already priced in?

      The CDMO business for small molecules grew 58 percent YoY in Q2FY26, helped by a ramp-up in sales from new manufacturing assets

    • Trade Spotlight: How should you trade L&T Finance, Bank of India, Nykaa, Axis Bank, Laurus Labs, and others on October 03?

      The market needs to surpass short- and medium-term moving averages for a persistent uptrend. Below are some short-term trading ideas to consider.

    • Laurus Labs Consolidated June 2025 Net Sales at Rs 1,569.57 crore, up 31.35% Y-o-Y

    • Laurus Labs Standalone June 2025 Net Sales at Rs 1,432.75 crore, up 28.28% Y-o-Y

    • Laurus Labs shares rise 7% on strong Q1 results, allotment of over 500 acres by Andhra govt

      On July 25, Laurus Labs reported a whopping 1,154% jump in its net profit in June quarter at Rs 163 crore

    • Trade Spotlight: How should you trade Apollo Hospitals, ASK Automotive, IndusInd Bank, Ashok Leyland, Laurus Labs, LT Foods, and others on June 30?

      Overall, the trend continues to favour the bulls, although some consolidation may occur following a two-week rally. Below are some short-term trading ideas to consider.

    • Laurus Labs: CDMO-led growth to enhance return ratios

      Drug discovery and development collaboration are the key drivers for the Indian CDMO industry.

    • Buy Laurus Labs; target of Rs 750: Motilal Oswal

      Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 750 in its research report dated April 24, 2025.

    • Buy Laurus Labs; target of Rs 750: Choice Equity Broking

      Choice Equity Broking is bullish on Laurus Lab recommended buy rating on the stock with a target price of Rs 750 in its research report dated April 25, 2025.

    • Laurus Labs Consolidated March 2025 Net Sales at Rs 1,720.30 crore, up 19.49% Y-o-Y

    • Laurus Labs Standalone March 2025 Net Sales at Rs 1,650.01 crore, up 16.65% Y-o-Y

    • Trade Spotlight: How should you trade Crompton Greaves Consumer, Tata Motors, Kotak Mahindra Bank, SRF, ITD Cementation, and others on March 13?

      The benchmark indices are likely to be rangebound in the upcoming sessions. Below are some trading ideas for the near term.

    • Stocks to Watch Today: TCS, Quess Corp, Power Grid Corporation, Eris Lifesciences, Omaxe, Kalpataru Projects, Biocon in focus on 7 March

      Stocks to Watch, Mar 7: Stocks like Tamilnad Mercantile Bank, NMDC, Jindal Stainless, Sudarshan Pharma Industries, Brigade Enterprises, Rail Vikas Nigam, RITES, Laurus Labs, Bharat Electronics, InterGlobe Aviation, Firstsource Solutions, TCPL Packaging, Avanti Feeds, Campus Activewear, and Balaji Phosphates will be in focus on March 7.

    • Laurus Labs shares surge 8% as Trump govt resumes funding for AIDS programme

      The Trump administration on January 24 halted disbursement of funds to programmes to treat HIV, malaria and other diseases in developing countries for at least 90 days.

    • Buy Laurus Labs; target of Rs 720: Motilal Oswal

      Motilal Oswal is bullish on Laurus Labs has recommended buy rating on the stock with a target price of Rs 720 in its research report dated January 25, 2025.

    • Laurus Labs Consolidated December 2024 Net Sales at Rs 1,415.05 crore, up 18.42% Y-o-Y

    • Laurus Labs assures no 'significant impact' of AIDS relief funding halt by Trump 2.0

      "If at all there may be funding challenge, the Company reasonably believes it will not affect the procurement of medications," said Laurus Labs.

    • Accumulate Laurus Labs; target of Rs 687: KR Choksey

      KR Choksey recommended accumulate rating on Laurus Labs with a target price of Rs 687 in its research report dated January 27, 2024.

    • Laurus Labs Standalone December 2024 Net Sales at Rs 1,265.19 crore, up 11.75% Y-o-Y

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347